LogicBio Therapeutics (OTCMKTS:LOGC) Sees Unusually-High Trading Volume – Here’s Why

LogicBio Therapeutics, Inc. (OTCMKTS:LOGC) saw unusually-strong trading volume on Thursday . Approximately 402,240 shares traded hands during trading, an increase of 189% from the previous session’s volume of 139,226 shares.The stock last traded at $14.82 and had previously closed at $14.90.

LogicBio Therapeutics Stock Performance

The stock has a market capitalization of $677.72 million, a price-to-earnings ratio of -20.30 and a beta of 2.11. The firm has a fifty day moving average of $11.11 and a 200 day moving average of $9.50. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.87 and a quick ratio of 1.24.

LogicBio Therapeutics (OTCMKTS:LOGC) last posted its earnings results on Thursday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.10). The firm had revenue of $33.60 million for the quarter, compared to analysts’ expectations of $33.60 million.

LogicBio Therapeutics Company Profile

LogicBio Therapeutics was a clinical-stage genetic medicine company focused on developing treatments for rare and serious genetic diseases. The company’s research centered on technologies designed to modify or deliver genetic material directly inside the body.

LogicBio’s principal technology platforms included GeneRide, an in vivo gene-insertion approach intended to enable long-term expression of therapeutic genes, and GeneWare, a genome-editing platform. Its lead investigational program, LB-001, was developed as a potential treatment for methylmalonic acidemia, a rare inherited metabolic disorder.

Founded in 2014 and headquartered in Cambridge, Massachusetts, LogicBio operated primarily as a biotechnology research and development company serving the rare-disease and genetic-medicine markets.